Mark Waer

7.8k total citations · 1 hit paper
247 papers, 6.0k citations indexed

About

Mark Waer is a scholar working on Immunology, Surgery and Transplantation. According to data from OpenAlex, Mark Waer has authored 247 papers receiving a total of 6.0k indexed citations (citations by other indexed papers that have themselves been cited), including 101 papers in Immunology, 86 papers in Surgery and 49 papers in Transplantation. Recurrent topics in Mark Waer's work include Immune Cell Function and Interaction (53 papers), T-cell and B-cell Immunology (51 papers) and Renal Transplantation Outcomes and Treatments (43 papers). Mark Waer is often cited by papers focused on Immune Cell Function and Interaction (53 papers), T-cell and B-cell Immunology (51 papers) and Renal Transplantation Outcomes and Treatments (43 papers). Mark Waer collaborates with scholars based in Belgium, United States and Portugal. Mark Waer's co-authors include Chantal Mathieu, Michel Vandeputte, Lut Overbergh, Dirk Valckx, Omer Rutgeerts, Philippe R. Koninckx, Roger Bouillon, Jozef Laureys, Didier J. Oosterlynck and Yuan Lin and has published in prestigious journals such as The Lancet, Nature Medicine and SHILAP Revista de lepidopterología.

In The Last Decade

Mark Waer

240 papers receiving 5.7k citations

Hit Papers

QUANTIFICATION OF MURINE ... 1999 2026 2008 2017 1999 100 200 300 400 500

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Mark Waer 2.4k 1.4k 1.3k 1.1k 912 247 6.0k
Michael Kurrer 3.6k 1.5× 473 0.3× 948 0.7× 563 0.5× 240 0.3× 87 7.3k
Francesco Puppo 2.6k 1.1× 588 0.4× 375 0.3× 284 0.3× 224 0.2× 124 4.7k
Raivo Uibo 1.1k 0.4× 219 0.2× 1.2k 0.9× 1.3k 1.2× 394 0.4× 180 4.1k
Jan Dutz 3.1k 1.3× 868 0.6× 675 0.5× 969 0.9× 58 0.1× 160 6.1k
Francesco Indiveri 3.2k 1.3× 674 0.5× 615 0.5× 355 0.3× 192 0.2× 215 5.9k
Daniel Benharroch 2.1k 0.9× 784 0.6× 355 0.3× 165 0.2× 518 0.6× 139 4.5k
Surendra Sharma 3.6k 1.5× 272 0.2× 253 0.2× 198 0.2× 564 0.6× 144 6.6k
Joshua M. Thurman 4.2k 1.7× 475 0.4× 782 0.6× 252 0.2× 77 0.1× 163 7.9k
Roberto Perricone 2.2k 0.9× 472 0.3× 157 0.1× 265 0.2× 198 0.2× 188 4.8k
Stephen I. Alexander 4.6k 1.9× 359 0.3× 1.4k 1.1× 635 0.6× 51 0.1× 186 8.6k

Countries citing papers authored by Mark Waer

Since Specialization
Citations

This map shows the geographic impact of Mark Waer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Waer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Waer more than expected).

Fields of papers citing papers by Mark Waer

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Waer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Waer. The network helps show where Mark Waer may publish in the future.

Co-authorship network of co-authors of Mark Waer

This figure shows the co-authorship network connecting the top 25 collaborators of Mark Waer. A scholar is included among the top collaborators of Mark Waer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark Waer. Mark Waer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Waer, Mark, et al.. (2024). Surgery in recurrent brain glioma, does it improve clinical outcome?. SHILAP Revista de lepidopterología. 39(1). 1 indexed citations
2.
Lin, Yuan, et al.. (2020). Donor Lymphocyte–Derived Natural Killer Cells Control MHC Class I–Negative Melanoma. Cancer Immunology Research. 8(6). 756–768. 4 indexed citations
3.
Lin, Yuan, Omer Rutgeerts, Xavier Sagaert, et al.. (2019). Solid Tumor–Induced Immune Regulation Alters the GvHD/GvT Paradigm after Allogenic Bone Marrow Transplantation. Cancer Research. 79(10). 2709–2721. 8 indexed citations
4.
Soma, Toshiya, et al.. (2008). The importance of persisting allo-stimulation for the maintenance of tolerance and regulatory T cells. American Journal of Transplantation. 8. 407–407. 1 indexed citations
5.
Li, Shengqiao, Yuan Lin, Dominique Bullens, et al.. (2007). Rapidly induced, T-cell–independent xenoantibody production is mediated by marginal zone B cells and requires help from NK cells. Blood. 110(12). 3926–3935. 32 indexed citations
6.
Takahashi, Kanji, Makiko Kawai, Mark Waer, Chantal Mathieu, & Jacques Pirenne. (2007). Calcineurin inhibitor immunosuppression: "Less and later is more". American Journal of Transplantation. 7. 482–482. 1 indexed citations
7.
Kawai, Makiko, Hiroaki Kitade, Chantal Mathieu, Mark Waer, & Jacques Pirenne. (2006). Differential effect of immunosuppressive drugs on the development of regulatory cells. American Journal of Transplantation. 313–313. 1 indexed citations
8.
Billiau, An, Yuan Lin, Lieve Moons, et al.. (2005). Role of growth arrest specific gene 6 in immune and non-immune aspects of vascular lesions occurring during delayed xenograft rejection. Xenotransplantation. 12(5). 382–383. 4 indexed citations
9.
Kitade, Hiroaki, et al.. (2004). Rapid presence of CD4+/CD45RC-regulatory cells in tolerated grafts: Evidence for a protective role in the tolerated tissues. American Journal of Transplantation. 4. 421–421. 3 indexed citations
11.
Koshiba, T, Hiroaki Kitade, Boudewijn Van Damme, et al.. (2003). Regulatory cell-mediated tolerance does not protect against chronic rejection. Transplantation. 76(3). 588–596. 33 indexed citations
12.
Stoffels, Katinka, Conny Gysemans, Mark Waer, et al.. (2002). Interleukin-1 receptor antagonist inhibits primary non-function and prolongs graft survival time of xenogeneic islets transplanted in spontaneously diabetic autoimmune NOD mice. Diabetologia. 4 indexed citations
13.
Kitade, Hiroaki, Mark Waer, Karel Geboes, et al.. (2002). Complete freedom from rejection, infection and drug toxicity after intestinal transplantation using a new tolerogenic protocol combined with low immunosuppression. Transplantation. 74. 1 indexed citations
14.
Casteels, Kristina, Conny Gysemans, Mark Waer, et al.. (1998). Effect of sex hormones on apoptosis in NOD mice: Link to autoimmunity. Diabetes. 47. 1 indexed citations
15.
Lin, Yuan, et al.. (1996). Xanthines: ideal immunosuppressants for combination with cyclosporine?. PubMed. 28(6). 3102–3102.
16.
Waer, Mark, et al.. (1985). Phenotypic and functional-analysis of suppressor cells in renal-transplant recipients receiving cyclosporine-a or preoperative total lymphoid irradiation. Transplantation Proceedings. 17(6). 2539–2542. 1 indexed citations
17.
Vanrenterghem, Yves, et al.. (1985). Are cyclosporine-treated hla-drw6-positive cadaveric kidney allograft recipients high responders. Transplantation Proceedings. 17(6). 2252–2253. 1 indexed citations
18.
Vanrenterghem, Yves, Mark Waer, & Paul Michielsen. (1985). A controlled trial of one month versus 3 months cyclosporine and conversion to azathioprine in renal-transplantation. Transplantation Proceedings. 17(1). 1162–1163. 1 indexed citations
19.
Vanrenterghem, Yves, L Roels, Antoon Lerut, et al.. (1985). Evaluation of cyclosporine in a center with high survival rates using conventional immunosuppression. Transplantation Proceedings. 17(6). 2666–2668. 2 indexed citations
20.
Vanrenterghem, Yves, Mark Waer, K. Kian Ang, et al.. (1983). Renal transplantation in diabetes after total lymphoid irradiation (TLI). Dialysis & Transplantation. 12(2). 104–105. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026